Objective:

To revive and reintroduce Triesence, an injectable suspension for ocular inflammatory conditions, to the market after a prolonged shortage due to supply chain issues and regulatory challenges.

Key Findings:

• Triesence was unavailable in the U.S. for over 2 years due to supply chain issues.
• Harrow secured a 5-year strategic supply agreement to ensure ongoing production.
• The formulation of Triesence remained unchanged, but manufacturing processes were updated to meet current standards.
• The shortage impacted younger surgeons' access to the product, forcing reliance on alternatives.

Interpretation:

Harrow's strategic approach to reviving Triesence involved significant investment in supply chain integrity and compliance with modern manufacturing standards, alongside community education, which is crucial for restoring its role in ophthalmic care.

Limitations:

• The article does not provide specific data on the market impact of Triesence's reintroduction.
• Limited information on the long-term sustainability of the supply chain beyond the initial 5-year agreement.
• Lack of data on the product's market performance post-reintroduction.

Conclusion:

Harrow's efforts to reintroduce Triesence demonstrate a commitment to restoring access to essential ophthalmic treatments while ensuring compliance with modern manufacturing standards.